An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection

European Journal of Immunology

Volumn 38, Issue 3, 2008, Pages 720-731

  Allenbach, Cindy ^a   Launois, Pascal ^a   Mueller, Christoph ^b   Tacchini Cottier, Fabienne ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Inflammation; Leishmania major; Neutrophils; TNF; Transmembrane

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; TUMOR NECROSIS FACTOR; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; INFLAMMATION; LEISHMANIA MAJOR; LEISHMANIASIS; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PARASITE CONTROL; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; C57BL MOUSE; DBA MOUSE; GENETICS; IMMUNOLOGY; LYMPH NODE; METABOLISM; MOUSE MUTANT; PARASITOLOGY; PATHOLOGY; PHYSIOLOGY; SKIN; SKIN LEISHMANIASIS; TH1 CELL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODY FORMATION; FEMALE; IMMUNOGLOBULIN G; INFLAMMATION; INTERFERON TYPE II; LEISHMANIASIS, CUTANEOUS; LYMPH NODES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUTROPHILS; NITRIC OXIDE SYNTHASE TYPE II; SKIN; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43649105672     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737662     Document Type: Article

References (76)

1. Sacks, D. and Noben-Trauth, N., The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2002. 2: 845-858.
2. Beil, W.J., Meinardus-Hager, G., Neugebauer, D.C. and Sorg, C., Differences in the onset of the inflammatory response to cutaneous leishmaniasis in resistant and susceptible mice. J. Leukoc. Biol. 1992. 52: 135-142.
3. + Th2 response in BALB/c mice infected with Leishmania major. J. Immunol. 2000. 165: 2628-2636.
4. Kollias, G., Douni, E., Kassiotis, G. and Kontoyiannis, D., On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. 1999. 169: 175-194.
5. Pfeffer, K., Matsuyama, T., Kundig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K. et al., Mice deficient for the 55-kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993. 73: 457-467.
6. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A. et al., Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993. 364: 798-802.
7. Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schreiber, R. et al., Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995. 2: 561-572.
8. Silva, J. S., Vespa, G. N., Cardoso, M. A., Aliberti, J. C. and Cunha, F. Q., Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect. Immun. 1995. 63: 4862-4867.
9. Senaldi, G., Yin, S., Shaklee, C. L., Piguet, P. F., Mak, T. W. and Ulich, T. R., Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette- Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J. Immunol. 1996. 157: 5022-5026.
10. Garcia, I., Miyazaki, Y., Marchal, G., Lesslauer, W. and Vassalli, P., High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: Synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur. J. Immunol. 1997. 27: 3182-3190.
11. Yap, G. S., Scharton-Kersten, T., Charest, H. and Sher, A., Decreased resistance of TNF receptor p55- and p75-deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo. J. Immunol. 1998. 160: 1340-1345.
12. Roach, D. R., Bean, A. G., Demangel, C., France, M. P., Briscoe, H. and Britton, W. J., TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 2002. 168: 4620-4627.
13. Liew, F. Y., Li, Y. and Millott, S., Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 1990. 145: 4306-4310.
14. Bogdan, C., Moll, H., Solbach, W. and Rollinghoff, M., Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur. J. Immunol. 1990. 20: 1131-1135.
15. Theodos, C. M., Povinelli, L., Molina, R., Sherry, B. and Titus, R. G., Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect. Immun. 1991. 59: 2839-2842.
16. Titus, R. G., Sherry, B. and Cerami, A., Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J. Exp. Med. 1989. 170: 2097-2104.
17. Liew, F. Y., Parkinson, C., Millott, S., Severn, A. and Carrier, M., Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 1990. 69: 570-573.
18. de Kossodo, S., Grau, G. E., Louis, J. A. and Muller, I., Tumor necrosis factor alpha (TNF-alpha) and TNF-beta and their receptors in experimental cutaneous leishmaniasis. Infect. Immun. 1994. 62: 1414-1420.
19. Garcia, I., Miyazaki, Y., Araki, K., Araki, M., Lucas, R., Grau, G. E., Milon, G. et al., Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur. J. Immunol. 1995. 25; 2401-2407.
20. Vieira, L. Q., Goldschmidt, M., Nashleanas, M., Pfeffer, K., Mak, T. and Scott, P., Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J. Immunol. 1996. 157: 827-835.
21. Nashleanas, M., Kanaly, S. and Scott, P., Control of Leishmania major infection in mice lacking TNF receptors. J. Immunol. 1998. 160: 5506-5513.
22. Kanaly, S. T., Nashleanas, M., Hondowiez, B. and Scott, P., TNF receptor p55 is required for elimination of inflammatory cells following control of intracellular pathogens. J. Immunol. 1999. 163: 3883-3889.
23. Chakour, R., Guler, R., Bugnon, M., Allenbaech, C., Garcia, I., Manuel, J., Louis, J. and Tacchini-Cottier, F., Both the Fas ligand and inducible nitric oxide synthase are needed for control of parasite replication within lesions in mice imfected with Leishmania major whereas the contribution of tumor necrosis factor is minimal. Infect. Immun. 2003. 71: 5287-5295.
24. Ritter, U., Mattner, J., Rocha, J. S., Bogdan, C. and Korner, H., The control of Leishmania (Leishmania) major by TNF in vivo is dependent on the parasite strain. Microbes Infect. 2004. 6: 559-565.
25. Wilhelm, P., Ritter, U., Labbow, S., Donhauser, N., Rollinghoff, M., Bogdan, C. and Korner, H., Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J. Immunol. 2001. 166: 4012-4019.
26. Barral-Netto, M., Badaro, R., Barral, A., Almeida, R. P., Santos, S. B., Badaro, F., Pedral-Sa,paio, D. et al., Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J, Infect. Dis. 1991. 163: 853-857.
27. Karplus, T. M., Jeronimo, S. M., Chang, H., Helms, B. K., Burns, T. L., Murray, J. C., Mitchell, A. A. et al., Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect. Immun. 2002. 70: 6919-6925.
28. Tumang, M. C., Keogh, C., Moldawer, L. L., Helfgott, D. C., Teitelbaum, R., Hariprashad, J. and Murray, H. W., Role and effect of TNF-alpha in experimental visceral leishmaniasis. J. Immunol. 1994. 153: 768-775.
29. Ribeiro-de-Jesus, A., Almeida, R. P., Lessa, H., Bacellar, O. and Carvalho, F.. M., Cytokine profile and pathology in human leishmaniasis. Braz. J. Med. Biol. Res. 1998. 31: 143-148.
30. Blackwell, J. M., Tumour necrosis factor alpha and mucocutaneous leishmaniasis. Parasitol. Today 1999. 15: 73-75.
31. Pirmez, C., Yamamura, M., Uyemura, K., Paes-Oliveira, M., Conceicao-Silva, F. and Modlin, R. L., Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 1993. 91: 1390-1395.
32. Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwietermian, W. D., Siegel, J. N. and Braun, M. M., Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutrahzing agent. N. Engl. J. Med. 2001. 345: 1098-1104.
33. Thi, T. L., O'Rourke, K. P., McWeeney, M., Burke, C. M., Sheehan, K. and Barry, M., Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 2002. 41: 951-952.
34. Fabre, S., Gibert, C., Lechiche, C., Dereure, J., Jorgensen, C. and Sany, J., Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin. Exp. Rheumatol. 2005. 23: 891-892.
35. Steed, P. M., Tansey, M. G., Zalevsky, J., Zhukovsky, E. A., Desjarlais, J. R., Szymkowski, D. E., Abbott, C. et al., Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003. 301: 1895-1898.
36. Spohn, G., Guler, R., Johansen, P., Keller, I., Jacobs, M., Beek, M., Rohner, F. et al., A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 2007. 178: 7450-7457.
37. Ruuls, S. R., Hoek, R. M., Ngo, V. N., McNeil, T., Lucian, L. A., Janatpour, M. J., Korner, H. et al., Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001. 15: 533-543.
38. Wilhelm, P., Wiede, F., Meissner, A., Donhauser, N., Bogdan, C. and Korner, H., TNF but not Fas ligand provides protective anti-L. major immunity in C57BL/6 mice. Microbes Infect. 2005. 7: 1461-1468.
39. Le Hir, M., Bluethmann, H., Kosco-Vilbois, M. H., Muller, M., di Padova, F., Moore, M., Ryffel, B. and Eugster, H. P., Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J. Exp. Med. 1996. 183: 2367-2372.
40. Marino, M.W., Dunn, A., Grail, D., Inglese, M., Noguchi, Y., Richards, E., Jungbluth, A. et al., Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 1997. 94: 8093-8098.
41. Sunderkotter, C., Kunz, M., Steinbrink, K., Meinardus-Hager, G., Goebeler, M., Bildau, H. and Sorg, C., Resistance of mice to experimental leishmaniasis is associated with more rapid appearance of mature macrophages in vitro and in vivo. J. Immunol. 1993. 151: 4891-4901.
42. Allenbach, C., Zufferey, C., Perez, C., Launois, P., Mueller, C. and Tacchini-Cottier, F., Macrophages induce neutrophil apoptosis through membrane TNF, a process amplified by Leishmania major. J. Immunol. 2006. 176: 6656-6664.
43. Charmoy, M., Megnekou, R., Allenbach, C., Zweifel, C., Perez, C., Monnat, K., Breton, M. et al., Leishmania major induces distinct neutrophil phenotypes in mice that are resistant or susceptible to infection. J. Leukoc. Biol. 2007. 82: 288-299.
44. Clark, I. A., How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 2007. 18: 335-343.
45. Bazzoni, F. and Beutler, B., The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996. 334: 1717-1725.
46. Kresse, M., Latta, M., Kunstle, G., Riehle, H. M., van Rooijen, N., Hentze, H., Tiegs, G. et al., Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. J. Immunol. 2005. 175: 4076-4083.
47. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S. et al., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995. 83: 793-802.
48. Olleros, M. L., Guler, R., Corazza, N., Vesin, D., Eugster, H. P., Marchal, G., Chavarot, P. et al., Transmembrane TNF induces an efficient cellmediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J. Immunol. 2002. 168: 3394-3401.
49. Woelbing, F., Kostka, S. L., Moelle, K., Belkaid, Y., Sunderkoetter, C., Verbeek, S., Waisman, A. et al., Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J. Exp. Med. 2006. 203: 177-188.
50. Zganiacz, A., Santosuosso, M., Wang, J., Yang, T., Chen, L., Anzulovic, M., Alexander, S. et al., TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J. Clin. Invest. 2004. 113: 401-413.
51. Olleros, M. L., Guler, R., Vesin, D., Parapanov, R., Marchal, G., Martinez-Soria, E., Corazza, N. et al., Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am. J. Pathol. 2005. 166: 1109-1120.
52. Watson, R. W., Rotstein, O. D., Nathens, A. B., Parodo, J. and Marshall, J. C., Neutrophil apoptosis is modulated by endothelial transmigration and adhesion molecule engagement. J. Immunol. 1997. 158: 945-953.
53. Biffl, W. L., Moore, E. E., Moore, F. A. and Barnett, C. C., Jr., Interleukin-6 suppression of neutrophil apoptosis is neutrophil concentration dependent. J. Leukoc. Biol. 1995. 58: 582-584.
54. Kettritz, R., Gaido, M. L., Haller, H., Luft, F. C., Jennette, C. J. and Falk, R. J., Interleukin-8 delays spontaneous and tumor necrosis factor-alphamediated apoptosis of human neutrophils. Kidney Int. 1998. 53: 84-91.
55. Simon, H. U., Neutrophil apoptosis pathways and their modifications in inflammation. Immunol. Rev. 2003. 193: 101-110.
56. Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P.W., Westcott, J. Y. and Henson, P. M., Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 1998. 101: 890-898.
57. Takeda, Y., Watanabe, H., Yonehara, S., Yamashita, T., Saito, S. and Sendo, F., Rapid acceleration of neutrophil apoptosis by tumor necrosis factor-alpha. Int. Immunol. 1993. 5: 691-694.
58. Watson, R. W., Redmond, H. P., Wang, J. H. and Bouchier-Hayes, D., Bacterial ingestion, tumor necrosis factor-alpha, and heat induce programmed cell death in activated neutrophils. Shock 1996. 5: 47-51.
59. Murray, J., Barbara, J. A., Dunkley, S. A., Lopez, A. F., Van Ostade, X., Condliffe, A. M., Dransfield, I. et al., Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: Requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood 1997. 90: 2772-2783.
60. Colotta, F., Re, F., Polentarutti, N., Sozzani, S. and Mantovani, A., Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992. 80: 2012-2020.
61. Keel, M., Ungethum, U., Steckholzer, U., Niederer, E., Hartung, T., Trentz, O. and Ertel, W., Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 1997. 90: 3356-3363.
62. Meszaros, A. J., Reichner, J. S. and Albina, J. E., Macrophage-induced neutrophil apoptosis. J. Immunol. 2000. 165: 435-441.
63. Saunders, B. M., Tran, S., Ruuls, S., Sedgwick, J. D., Briscoe, H. and Britton, W. J., Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J. Immunol. 2005. 174: 4852-4859.
64. Musicki, K., Briscoe, H., Tran, S., Britton, W. J. and Saunders, B. M., Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infect. Immun. 2006. 74: 3180-3189.
65. Torres, D., Janot, L., Quesniaux, V. F., Grivennikov, S. I., Maillet, I., Sedgwick, J. D., Ryffel, B. and Erard, F., Membrane tumor necrosis factor confers partial protection to Listeria infection. Am. J. Pathol. 2005. 167: 1677-1687.
66. Ward, A. and Clissold, S. P., Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987. 34: 50-97.
67. Doherty, G. M., Jensen, J. C., Alexander, H. R., Buresh, C. M. and Norton, J. A., Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991. 110: 192-198.
68. Lessa, H. A., Machado, P., Lima, F., Cruz, A. A., Bacellar, O., Guerreiro, J. and Carvalho, E. M., Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am. J. Trop. Med. Hyg. 2001. 65: 87-89.
69. Bafica, A., Oliveira, F., Freitas, L. A., Nascimento, E. G. and Barral, A., American cutaneous leishmaniasis unresponsive to antimonial drugs: Successful treatment using combination of N-methylglucamine antimoniate plus pentoxifylline. Int. J. Dermatol. 2003. 42: 203-207.
70. Romani-Costa, V., Sanchez, C., Moya, F. and Estany, C., Visceral leishmaniasis related to infliximab administration. Enferm. Infecc. Microbiol. Clin. 2004. 22: 310.
71. Bagalas, V., Kioumis, I., Argyropoulou, P. and Patakas, D., Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin. Rheumatol. 2007. 26: 1344-1345.
72. Pizzorni, C., Secchi, M. E. and Cutolo, M., Leishmaniasis in rheumatoid arthritis. Reumatismo 2007. 59: 235-239.
73. Titus, R. G., Marchand, M., Boon, T. and Louis, J. A., A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985. 7: 545-555.
74. Taswell, C., Limiting dilution assays for the determination of immuno-competent cell frequencies. I. Data analysis. J. Immunol. 1981. 126: 1614-1619.
75. + T helper differentiation. Eur. J. Immunol. 2004. 34: 1588-1596.
76. Lopez, A. F., Strath, M. and Sanderson, C. J., Differentiation antigens on mouse eosinophils and neutrophils identified by monoclonal antibodies. Br. J. Haematol. 1984. 57: 489-494.